TREATMENT OF IRRITABILITY IN SUBJECTS WITH AUTISM SPECTRUM DISORDERS WITH MODERATE TO SEVERE ANXIETY AND/OR SOCIAL AVOIDANCE
The present technology relates to a method of treating one or more behavioral symptoms of autism spectrum disorder (ASD) in a subject by administering an effective amount of cannabidiol (CBD). Specifically, subjects having moderate to severe ASD and relatively high social avoidance and/or anxiety are more likely to show a reduction in irritability when treated with CBD.
1 . A method of treating irritability in a subject diagnosed with autism spectrum disorder (ASD), the method comprising:
administering an effective amount of cannabidiol (CBD) to the subject, wherein the subject has a high baseline ABC-C irritability score, and wherein the subject also has a high baseline ABC-CFXS social avoidance score and/or a high baseline Parent Rated Anxiety Scale for ASD (PRAS-ASD),
wherein irritability in the subject is treated.
2 . The method according to claim 1 , wherein the subject has a baseline ABC-C irritability score of greater than 12.
3 . The method according to claim 1 , wherein the subject has a baseline ABC-CFXS social avoidance score of greater than 5.
4 . The method according to claim 1 , wherein the subject has a baseline Parent Rated Anxiety Scale for ASD (PRAS-ASD) score of greater than 25.
5 . The method according to claim 1 , wherein the subject is diagnosed with moderate to severe ASD.
6 . The method according to claim 1 , wherein the subject has an Autism Diagnostic Observation Schedule, 2nd Edition (ADOS-2) comparison score of greater than or equal to 3.
7 . The method according to claim 1 , wherein the CBD is administered transdermally.
8 . The method according to claim 1 , wherein the CBD is synthetic CBD.
9 . The method according to claim 1 , wherein the CBD is botanically derived CBD.
10 . The method according to claim 1 , wherein the effective amount of CBD is a 250 mg total daily dose.
11 . The method according to claim 1 , wherein the effective amount of CBD is a 500 mg total daily dose.
12 . The method according to claim 1 , wherein the effective amount of CBD is a 750 mg total daily dose.
13 . The method according to claim 1 , wherein the effective amount of CBD is a 1000 mg total daily dose.
14 . The method according to claim 1 , wherein the effective amount is administered in two daily doses.
15 . The method according to claim 1 , wherein the CBD is administered in a pharmaceutically acceptable preparation that does not contain THC.
16 . The method according to claim 1 , wherein the subject is also diagnosed with Fragile X Syndrome (FXS).